Igor Sinelnikov

Igor Sinelnikov

Auto-generated profile, based on publicly available information

Igor Sinelnikov

Melanoma Unit Limited liability company

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
ITIlya Tsimafeyeu
Ilya Tsimafeyeu
LDLev Demidov
Lev Demidov
GKGalina Kharkevich
Galina Kharkevich
NPNatalia Petenko
Natalia Petenko
VGVladimir Galchenko
Vladimir Galchenko
UNUladzislau Naidzionak
Uladzislau Naidzionak
Although significant progress has been made for metastatic renal cell carcinoma (MRCC), very little progress has been achieved for non-clear cell MRCC. Thus, we performed a phase II, multicenter trial of capecitabine in patients with non-clear cell MRCC. Adult patients with MRCC containing <50% of clear cells were eligible. All patients received oral capecitabine (1,250 mg/m) twice daily for 14 days, followed by 14 days of rest. Primary end point was objective response rate. On the basis of Chen and Ng 2-stage accrual design, maximum planned enrollment was 51 patients. This study is registered with ClinicalTrials.gov, NCT01182142. Fifty-one patients enrolled between February 2006 and January 2009. Most patients were men (72.5%), who had papillary RCC (76.5%), Memorial Sloan Kettering Cancer Center intermediate prognosis (86%), and had not been treated earlier (92%). The objective response rate was 26%. Two patients (4%) had a complete response. Stable disease was achieved in 24 (47%) patients. The median progression-free survival was 10.1 months [95% confidence interval (CI), 8.7-11.5], and overall survival was 18.3 months (95% CI, 15.5-21.1). The 1-year overall survival was 71% (95% CI, 63%-79%). Major grades 3 to 4, treatment-related toxicities included diarrhea (2%), esophageal mucosal inflammation (2%), hand-foot syndrome (4%), thrombocytopenia (9.8%), and neutropenia (8%). No patients were withdrawn because of laboratory abnormalities. Capecitabine has clinical activity in MRCC patients who have non-clear cell histology and a good or intermediate prognosis. Additional prospective randomized trial comparing capecitabine with placebo is required.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ISIgor Samoylenko
Igor Samoylenko
GKGalina Kharkevich
Galina Kharkevich
NPNatalia N. Petenko
Natalia N. Petenko
KOKristina V. Orlova
Kristina V. Orlova
ISIgor Sinelnikov
Igor Sinelnikov
LDLev V. Demidov
Lev V. Demidov
9552Background: Metastatic melanoma remains a disease with poor prognosis even in patients with BRAF mutation, treated by BRAF/MEK inhibitors. In many countries immune checkpoints inhibitors which could be used for 2nd line treatment are not registered, or not reimbursed. At the same time, experimantal evidence supports enhancing the effectiveness of chemotherapy after blocking the MAP-kinase pathway. We evaluated the immediate effectiveness of chemotherapy in patients after progression or intolerance on BRAF/MEK inhibitors. Methods: We conducted a retrospective analysis of all patients (pts) who received paclitaxel 175 mg / m2 day1 + carboplatin AUC = 5 day 1 (PC) from January 1 2012 to December 30 2015 (n = 51). Group 1 (n = 22) was treated with BRAF / MEK inhibitors (vemurafenib, dabrafenib, trametinib, encorafenib or binimetinib) before PC, group 2 (n = 29) received no inhibitors of BRAF / MEK prior to PC. Results: Both groups did not differ in demographic characteristics (mean age 51.5 ± 12,7 years i...

13 November 2019 in Surgery and Oncology
Verified
Journal Article
Open access
PDF file
AKAlexey Kotelnikov
Alexey Kotelnikov
DPD. V. Podluzhnyy
D. V. Podluzhnyy
IPI. S. Proskuryakov
I. S. Proskuryakov
ISI. E. Sinelnikov
I. E. Sinelnikov
NPNatalia N. Petenko
Natalia N. Petenko
EVE. R. Virshke
E. R. Virshke
This article presents the experience of surgical management of pancreatic and colon metastases from kidney cancer, detected 10 years after nephrectomy. Atypical resection of the pancreas combined with right-sided hemicolectomy was performed. The postoperative period turned out uneventful. Histological examination showed that lesions of pancreas and colon were metastases from a clear renal cell carcinoma. Disease progression was noted 2 years after surgery. The patient received appropriate treatment and was alive for 14 years after surgery.

6 February 2025 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Closed access
KUKseniia A. Uskova
Kseniia A. Uskova
VDVeniamin I. Dardyk
Veniamin I. Dardyk
OGOxana Ye. Garanina
Oxana Ye. Garanina
ISIgor E. Sinelnikov
Igor E. Sinelnikov
GSGamayunov Sergey
Gamayunov Sergey
ГВГамаюнов Сергей Викторович
Гамаюнов Сергей Викторович
BACKGROUND: In recent years, neural networks have become an integral part of many fields, including medicine. However, the effectiveness of these models directly depends on the quality of the training data on which they are trained. Creating and maintaining a high-quality training dataset is a critical step in the development process of neural networks. AIM: The aim of the research is to identify the key characteristics of the training database for the neural network that influence its subsequent sensitivity and specificity. MATERIALS AND METHODS: A database of verified images of skin neoplasms was created to train a neural network to implement it in large-scale screening examinations. In the first phase of the study, a database was created to train a neural network to classify images of skin neoplasms (NSCa). Between 2017 and 2019, 7,680 digital images were collected from 6,892 patients with verified diagnoses: 5,316 (69,22%) confirmed by pathological examination, and 2,364 (30,78%)) confirmed clinically and dermatoscopically. A dataset containing 7,680 verified clinical images of skin neoplasms was created, and 1,680 images constituted the test sample for analyzing the model's effectiveness. The performance indicators of NSCa were as follows: sensitivity (Se): 70.47%; specificity (Sp): 79.86%; diagnostic accuracy (Ac): 74.68%. Due to the low sensitivity and specificity rates, the following steps were taken: (1) an additional round of training was conducted; (2) image quality control methods were developed; (3) a detection neural network was created, and (4) a new neural (NSCb) was established. RESULTS: The neural network, trained on a verified dataset of clinical images of benign and malignant skin neoplasms and having undergone multiple rounds of training, operates with a sensitivity of 85.32–86.97% and a specificity of 87.59–88.92%. These rates exceed the sensitivity and specificity of skin neoplasm diagnoses made by non-oncological specialists using the naked eye, allowing for the use of this method in population screening. Following the retraining of the neural network and the establishment of NSCb, the creation of neural network, and the development of image quality control methods, an increase in the sensitivity and specificity of the neural network's performance was observed. CONCLUSION: The use of artificial intelligence as a physician's assistant imposes quite high requirements on the performance parameters of the neural network. Mechanical learning, even on a large volume of verified data, did not achieve the desired results. The sequential work aimed at improving the parameters involved conducting an additional round of training, developing image quality control methods, and creating a detection neural network and a classification neural network. As a result, the trained neural network operates with a sensitivity of 85.32% to 86.97% and a specificity of 87.59% to 88.92%, which has enabled the use of the trained neural network as a tool for population screening.